GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » PS Ratio

Ovid Therapeutics (Ovid Therapeutics) PS Ratio : 500.00 (As of May. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ovid Therapeutics's share price is $3.00. Ovid Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Hence, Ovid Therapeutics's PS Ratio for today is 500.00.

Good Sign:

Ovid Therapeutics Inc stock PS Ratio (=500) is close to 1-year low of 453.33

The historical rank and industry rank for Ovid Therapeutics's PS Ratio or its related term are showing as below:

OVID' s PS Ratio Range Over the Past 10 Years
Min: 0.86   Med: 88.1   Max: 1865
Current: 500

During the past 9 years, Ovid Therapeutics's highest PS Ratio was 1865.00. The lowest was 0.86. And the median was 88.10.

OVID's PS Ratio is ranked worse than
94.3% of 1000 companies
in the Biotechnology industry
Industry Median: 9.095 vs OVID: 500.00

Ovid Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Warning Sign:

Ovid Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ovid Therapeutics was -71.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -69.70% per year.

During the past 9 years, Ovid Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -69.70% per year. The lowest was -69.70% per year. And the median was -69.70% per year.

Back to Basics: PS Ratio


Ovid Therapeutics PS Ratio Historical Data

The historical data trend for Ovid Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics PS Ratio Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only - 10.69 1.05 88.57 536.67

Ovid Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.57 1,290.00 1,093.33 768.00 536.67

Competitive Comparison of Ovid Therapeutics's PS Ratio

For the Biotechnology subindustry, Ovid Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's PS Ratio falls into.



Ovid Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ovid Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.00/0.006
=500.00

Ovid Therapeutics's Share Price of today is $3.00.
Ovid Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ovid Therapeutics  (NAS:OVID) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ovid Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics (Ovid Therapeutics) Business Description

Traded in Other Exchanges
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Executives
Jason Tardio officer: Chief Commercial Officer 1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald director C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit officer: CMO and PMO C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole director 200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona officer: Chief Business Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone officer: SVP, General Counsel 1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein director C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward officer: SVP and General Counsel C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly officer: VP, Finance & Corp. Controller 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854